Conceptualizing an Economic Model Structure for Parkinson's Disease
Author(s)
Monica Ruoss, M.A.1, Anna Kotzeva, MPH, MD1, Anshul Shah, MS Pharmaceutical Administration2, Saifuddin M. Kharawala, MBBS2, Anadi Mahajan, M.Pharm2, C Simone Sutherland, BSc, MSc, PhD1.
1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2Bridge Medical Consulting Ltd, London, United Kingdom.
1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2Bridge Medical Consulting Ltd, London, United Kingdom.
OBJECTIVES: Parkinson's Disease (PD) is a progressive neurodegenerative disorder that significantly impacts both motor and non-motor functions in patients; while also imposing a considerable burden on caregivers who play a critical role in disease management (“Staunton et al. 2022”). A comprehensive understanding of the disease's natural history and progression is essential for robust economic models used in health technology assessment (HTA) decision-making. This study aims to establish a framework for economic evaluations of PD interventions from a societal perspective to support informed decision-making.
METHODS: Sources of evidence for the model included (i) a comprehensive literature review of recent cost-effectiveness models (CEMs) for PD and recommendations (“Dams et al. 2023“), (ii) the results from the consensus conceptual model of meaningful symptoms and functional impacts in early PD (“Mammen et al. 2025“) and (iii) ISPOR conceptual modelling best practices guidelines (“Roberts et al. 2012“).
RESULTS: Currently, most published CE models are Markov models with several health states: Hoehn and Yahr (HY) differentiated by daily 'off time,' and death. These models predominantly focus on advanced PD and often exclude a societal perspective (“Dams et al. 2023“).We propose a cost-effectiveness model (CEM) structure for PD that illustrates the economic impact on societal elements (e.g. healthcare costs, patient and caregiver productivity, family and caregiver health benefits, etc.) during the early and late stages of PD. The model should consider both motor and non-motor symptoms to provide a comprehensive view of an intervention’s efficacy on disease progression and contribution to sustainable healthcare solutions.
CONCLUSIONS: Based on previous economic evaluations and established patient health outcomes, this study proposes a CE model structure for PD that: integrates societal perspectives, engages in early discussions among all the relevant stakeholders, provides support for informed decisions that improve access, and alleviates burden on the health system for PD.
METHODS: Sources of evidence for the model included (i) a comprehensive literature review of recent cost-effectiveness models (CEMs) for PD and recommendations (“Dams et al. 2023“), (ii) the results from the consensus conceptual model of meaningful symptoms and functional impacts in early PD (“Mammen et al. 2025“) and (iii) ISPOR conceptual modelling best practices guidelines (“Roberts et al. 2012“).
RESULTS: Currently, most published CE models are Markov models with several health states: Hoehn and Yahr (HY) differentiated by daily 'off time,' and death. These models predominantly focus on advanced PD and often exclude a societal perspective (“Dams et al. 2023“).We propose a cost-effectiveness model (CEM) structure for PD that illustrates the economic impact on societal elements (e.g. healthcare costs, patient and caregiver productivity, family and caregiver health benefits, etc.) during the early and late stages of PD. The model should consider both motor and non-motor symptoms to provide a comprehensive view of an intervention’s efficacy on disease progression and contribution to sustainable healthcare solutions.
CONCLUSIONS: Based on previous economic evaluations and established patient health outcomes, this study proposes a CE model structure for PD that: integrates societal perspectives, engages in early discussions among all the relevant stakeholders, provides support for informed decisions that improve access, and alleviates burden on the health system for PD.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE151
Topic
Economic Evaluation
Disease
Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas